Truist raised the firm’s price target on CVS Health (CVS) to $102 from $98 and keeps a Buy rating on the shares. The company reported strong Q1 results while its Medicare Advantage commentary was constructive, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $101 from $93 at Barclays
- CVS Health price target raised to $100 from $95 at BofA
- CVS Health price target raised to $100 from $97 at UBS
- CVS Health reports Q1 adjusted EPS $2.57, consensus $2.21
- CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20